A Multicentre, Open-Label, Prospective Long-Term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia.

Trial Profile

A Multicentre, Open-Label, Prospective Long-Term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms SPECTRUM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Jun 2012 Additional trial location (Hong Kong) added as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top